Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Sclerosis: Update Bulletin #3 [August 2018]

Product Code:
596200977
Publication Date:
August 2018
Format:
PDF
Price:
$1,095

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: TG Therapeutics announcing updated results from a Phase II multicentre trial of ublituximab (TG 1101) in relapsing forms of multiple sclerosis (RMS); Roche presenting new Phase III data analyses for Ocrevus (ocrelizumab), and announcing the initiation of two additional Phase IIIb studies; as well as Alkermes announcing receipt of a US$50 million payment from Biogen relating to diroximel fumarate (formerly ALKS 8700) following Biogen's review of preliminary gastrointestinal tolerability data.

Business Questions:

• What are KOLs’ reactions to the updated Phase II results for ublituximab in patients with relapsing forms of MS?
• According to KOLs, is ublituximab’s shorter infusion time an advantage?
• Could ublituximab compete with Ocrevus and ofatumumab?
• How do KOLs view the new data analyses showing Ocrevus may provide meaningful disability benefits such as delay in the need for a wheelchair for people with PPMS?
• What do the experts think of the two new Ocrevus Phase IIIb trials, ORATORIO-HAND and CONSONANCE?
• According to experts, how clinically attractive is diroximel fumarate and what potential challenges need to be considered in order to position this therapy?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved